Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.40
IRWD's Cash to Debt is ranked higher than
71% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IRWD: 1.40 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: 420.39
Current: 1.4

1.1
420.39
Equity to Asset 0.27
IRWD's Equity to Asset is ranked higher than
50% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IRWD: 0.27 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.63
Current: 0.27

-1.86
0.63
F-Score: 4
Z-Score: 0.67
M-Score: -1.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -221.58
IRWD's Operating margin (%) is ranked higher than
50% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. IRWD: -221.58 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -221.58

-1101.36
-48.43
Net-margin (%) -248.07
IRWD's Net-margin (%) is ranked higher than
50% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. IRWD: -248.07 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -248.07

-1192.31
-48.34
ROE (%) -167.60
IRWD's ROE (%) is ranked lower than
53% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. IRWD: -167.60 )
IRWD' s 10-Year ROE (%) Range
Min: -299.34   Max: -48.14
Current: -167.6

-299.34
-48.14
ROA (%) -54.22
IRWD's ROA (%) is ranked higher than
51% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. IRWD: -54.22 )
IRWD' s 10-Year ROA (%) Range
Min: -107.22   Max: -22.85
Current: -54.22

-107.22
-22.85
ROC (Joel Greenblatt) (%) -490.15
IRWD's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. IRWD: -490.15 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.79   Max: -194.55
Current: -490.15

-672.79
-194.55
Revenue Growth (3Y)(%) -5.30
IRWD's Revenue Growth (3Y)(%) is ranked higher than
58% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. IRWD: -5.30 )
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -5.3
Current: -5.3

EBITDA Growth (3Y)(%) 27.50
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: 27.50 )
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 52
Current: 27.5

0
52
EPS Growth (3Y)(%) 28.80
IRWD's EPS Growth (3Y)(%) is ranked higher than
90% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. IRWD: 28.80 )
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 54.3
Current: 28.8

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IRWD Guru Trades in Q1 2014

John Burbank 16,207 sh (New)
Vanguard Health Care Fund 3,901,498 sh (+15.97%)
» More
Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

IRWD Guru Trades in Q3 2014

Steven Cohen 1,292,500 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

IRWD Guru Trades in Q4 2014

Steven Cohen 1,500,100 sh (+16.06%)
Vanguard Health Care Fund 4,166,598 sh (+6.79%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$12.17 - $15.69 $ 15.4513%0
Joel Greenblatt 2014-06-30 New Buy0.01%$9.71 - $15.5 $ 15.4519%27789
John Burbank 2014-06-30 Sold Out 0.01%$9.71 - $15.5 $ 15.4519%0
John Burbank 2014-03-31 New Buy0.01%$11.43 - $15.35 $ 15.4515%16207
Vanguard Health Care Fund 2013-06-30 Add 48.42%0.04%$9.93 - $18.17 $ 15.457%3238136
Lee Ainslie 2013-03-31 Sold Out 0.34%$11.08 - $18.85 $ 15.454%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 27.40
IRWD's Forward P/E is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.61 vs. IRWD: 27.40 )
N/A
P/B 24.52
IRWD's P/B is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. IRWD: 24.52 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 24.52

5.46
46.91
P/S 28.09
IRWD's P/S is ranked higher than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. IRWD: 28.09 )
IRWD' s 10-Year P/S Range
Min: 2.65   Max: 75.05
Current: 28.09

2.65
75.05
EV-to-EBIT -11.91
IRWD's EV-to-EBIT is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.12 vs. IRWD: -11.91 )
IRWD' s 10-Year EV-to-EBIT Range
Min: -40   Max: -4.2
Current: -11.91

-40
-4.2
Current Ratio 4.79
IRWD's Current Ratio is ranked higher than
84% of the 896 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.45 vs. IRWD: 4.79 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 5.58
Current: 4.79

2.33
5.58
Quick Ratio 4.70
IRWD's Quick Ratio is ranked higher than
87% of the 896 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. IRWD: 4.70 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 5.04
Current: 4.7

2.33
5.04
Days Inventory 218.42
IRWD's Days Inventory is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. IRWD: 218.42 )
IRWD' s 10-Year Days Inventory Range
Min: 193.31   Max: 1266.91
Current: 218.42

193.31
1266.91
Days Sales Outstanding 0.05
IRWD's Days Sales Outstanding is ranked higher than
100% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.09 vs. IRWD: 0.05 )
IRWD' s 10-Year Days Sales Outstanding Range
Min: 0.05   Max: 889.76
Current: 0.05

0.05
889.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 772.50
IRWD's Price/Net Cash is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 772.50 )
IRWD' s 10-Year Price/Net Cash Range
Min: 9.67   Max: 766
Current: 772.5

9.67
766
Price/Net Current Asset Value 386.25
IRWD's Price/Net Current Asset Value is ranked higher than
51% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 386.25 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 9.5   Max: 383
Current: 386.25

9.5
383
Price/Tangible Book 24.52
IRWD's Price/Tangible Book is ranked higher than
52% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. IRWD: 24.52 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 6.43   Max: 36.28
Current: 24.52

6.43
36.28
Price/Median PS Value 1.30
IRWD's Price/Median PS Value is ranked higher than
53% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. IRWD: 1.30 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.68
Current: 1.3

0.38
2.68
Earnings Yield (Greenblatt) -8.40
IRWD's Earnings Yield (Greenblatt) is ranked higher than
54% of the 923 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IRWD: -8.40 )
IRWD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.9   Max: 0
Current: -8.4

-8.9
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for NAS:IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
IRONWOOD PHARMACEUTICALS INC Financials Feb 25 2015
Ironwood Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference Feb 23 2015
10-K for Ironwood Pharmaceuticals, Inc. Feb 20 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 18 2015
Ironwood Pharmaceuticals (IRWD) Falls: Stock Goes Down 5.3% - Tale of the Tape Feb 17 2015
Ironwood Pharmaceuticals, Inc. (IRWD): New Analyst Report from Zacks Equity Research - Zacks Equity... Feb 16 2015
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog Feb 13 2015
Ironwood reports 4Q loss Feb 12 2015
Ironwood reports 4Q loss Feb 12 2015
Ironwood Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Feb 12 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 12 2015
Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update Feb 12 2015
Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update Feb 12 2015
Q4 2014 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close Feb 12 2015
Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory... Feb 04 2015
Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call Jan 29 2015
Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call Jan 29 2015
Why Earnings Season Could Be Great for Ironwood Pharmaceuticals (IRWD) - Tale of the Tape Jan 16 2015
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Jan 05 2015
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Jan 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK